Research has found that Tofacitinib is able to keep the expression of inflammatory factors to a certain extent, thus reducing the damage of inflammation to articular chondrocytes.[32] Clenoliximab is a chimeric monoclonal antibody against CD4 from rhesus monkeys, which has immunomodulatory effects.[33] Baricitinib is a Janus kinase (JAK) inhibitor used for the treatment of moderate to severe rheumatoid arthritis that does not respond well to at least one TNF antagonist. This evidence concerns the gene CD4 and rheumatoid arthritis.